Cover Image
Market Research Report

Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 915885
Published Content info 160 Pages
Delivery time: 1-2 business days
Price
Back to Top
Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024
Published: November 5, 2019 Content info: 160 Pages
Description

About this market

Technavio's vaccines market analysis considers sales from both prophylactic vaccines and therapeutic vaccine types. Our analysis also considers the sales of vaccines in Asia, Europe, North America, and ROW. In 2019, the prophylactic vaccines segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high safety and efficacy will play a significant role in the prophylactic vaccines segment to maintain its market position. Also, our global vaccines market report looks at factors such as increased funding for vaccine development and new vaccine launches, approval of vaccines and strong pipeline, and increasing use of adjuvants in vaccines. However, high costs of vaccine research, development, and manufacturing, product recalls, and safety concerns may hamper the growth of the vaccines industry over the forecast period.

Overview

Increasing the use of adjuvants in vaccines

With the increasing use of vaccines to treat and prevent life-threatening diseases, vendors are focusing on strategies for the development of effective new vaccines and usage of suitable adjuvants. They work by improving the humoral and cell-mediated immune response to vaccine antigens. The rise of the use of adjuvants, such as immunologic adjuvants, in new vaccines has increased to combat emerging new pathogens and re-emerging old pathogens. The demand for such vaccines is also high because of their long-lasting protective immune response. This will lead to the expansion of the global vaccines market at a CAGR of almost 7% during the forecast period.

Development of nanoparticle vaccines

The nanoparticle-based vaccines have higher immunization and targeted delivery attributes. This has led the vendors to invest in R&D of nanoparticle vaccines due to the ongoing research to develop vaccines against specific diseases. For instance, prophylactic vaccines are associated with the risk of regaining their pathogenicity under certain immunocompromised conditions. This limitation can be overcome by using nanoparticle vaccines. Such development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global vaccines market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of a few major players, the global vaccines market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading vaccines manufacturers, that include Bavarian Nordic AS, CSL Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novavax Inc., Pfizer Inc., and Sanofi

Also, the vaccine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR40041

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Prophylactic vaccines - Market size and forecast 2019-2024
  • Therapeutic vaccines - Market size and forecast 2019-2024
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • R&D of novel vaccines
  • Development of nanoparticle vaccines
  • Advancement in vaccine delivery system

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bavarian Nordic AS
  • CSL Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Type - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Prophylactic vaccines - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Prophylactic vaccines - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Therapeutic vaccines - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Therapeutic vaccines - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2019-2024 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bavarian Nordic AS - Vendor overview
  • Exhibit 49: Bavarian Nordic AS - Business segments
  • Exhibit 50: Bavarian Nordic AS - Organizational developments
  • Exhibit 51: Bavarian Nordic AS - Geographic focus
  • Exhibit 52: Bavarian Nordic AS - Key offerings
  • Exhibit 53: Bavarian Nordic AS - Key customers
  • Exhibit 54: CSL Ltd. - Vendor overview
  • Exhibit 55: CSL Ltd. - Business segments
  • Exhibit 56: CSL Ltd. - Organizational developments
  • Exhibit 57: CSL Ltd. - Geographic focus
  • Exhibit 58: CSL Ltd. - Segment focus
  • Exhibit 59: CSL Ltd. - Key offerings
  • Exhibit 60: CSL Ltd. - Key customers
  • Exhibit 61: Emergent BioSolutions Inc. - Vendor overview
  • Exhibit 62: Emergent BioSolutions Inc. - Business segments
  • Exhibit 63: Emergent BioSolutions Inc. - Organizational developments
  • Exhibit 64: Emergent BioSolutions Inc. - Key offerings
  • Exhibit 65: Emergent BioSolutions Inc. - Key customers
  • Exhibit 66: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 67: GlaxoSmithKline Plc - Business segments
  • Exhibit 68: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 69: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 70: GlaxoSmithKline Plc - Segment focus
  • Exhibit 71: GlaxoSmithKline Plc - Key offerings
  • Exhibit 72: GlaxoSmithKline Plc - Key customers
  • Exhibit 73: Inovio Pharmaceuticals Inc. - Vendor overview
  • Exhibit 74: Inovio Pharmaceuticals Inc. - Business segments
  • Exhibit 75: Inovio Pharmaceuticals Inc. - Organizational developments
  • Exhibit 76: Inovio Pharmaceuticals Inc. - Key offerings
  • Exhibit 77: Inovio Pharmaceuticals Inc. - Key customers
  • Exhibit 78: Merck & Co. Inc. - Vendor overview
  • Exhibit 79: Merck & Co. Inc. - Business segments
  • Exhibit 80: Merck & Co. Inc. - Organizational developments
  • Exhibit 81: Merck & Co. Inc. - Geographic focus
  • Exhibit 82: Merck & Co. Inc. - Segment focus
  • Exhibit 83: Merck & Co. Inc. - Key offerings
  • Exhibit 84: Merck & Co. Inc. - Key customers
  • Exhibit 85: Mitsubishi Tanabe Pharma Corp. - Vendor overview
  • Exhibit 86: Mitsubishi Tanabe Pharma Corp. - Business segments
  • Exhibit 87: Mitsubishi Tanabe Pharma Corp. - Organizational developments
  • Exhibit 88: Mitsubishi Tanabe Pharma Corp. - Geographic focus
  • Exhibit 89: Mitsubishi Tanabe Pharma Corp. - Key offerings
  • Exhibit 90: Mitsubishi Tanabe Pharma Corp. - Key customers
  • Exhibit 91: Novavax Inc. - Vendor overview
  • Exhibit 92: Novavax Inc. - Business segments
  • Exhibit 93: Novavax Inc. - Organizational developments
  • Exhibit 94: Novavax Inc. - Key offerings
  • Exhibit 95: Novavax Inc. - Key customers
  • Exhibit 96: Pfizer Inc. - Vendor overview
  • Exhibit 97: Pfizer Inc. - Business segments
  • Exhibit 98: Pfizer Inc. - Organizational developments
  • Exhibit 99: Pfizer Inc. - Geographic focus
  • Exhibit 100: Pfizer Inc. - Segment focus
  • Exhibit 101: Pfizer Inc. - Key offerings
  • Exhibit 102: Pfizer Inc. - Key customers
  • Exhibit 103: Sanofi - Vendor overview
  • Exhibit 104: Sanofi - Business segments
  • Exhibit 105: Sanofi - Organizational developments
  • Exhibit 106: Sanofi - Geographic focus
  • Exhibit 107: Sanofi - Segment focus
  • Exhibit 108: Sanofi - Key offerings
  • Exhibit 109: Sanofi - Key customers
  • Exhibit 110: Validation techniques employed for market sizing
  • Exhibit 111: Definition of market positioning of vendors
Back to Top